Katja Rohwedder

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin

Michael A. Nauck, Stefano Del Prato, Juris J. Meier et al. · Diabetes Care · 2011 · 527 citations · Full text

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

John Wilding, Vincent Woo, Katja Rohwedder et al. · Diabetes Obesity and Metabolism · 2013 · 295 citations · Full text

Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data

Stefano Del Prato, Michael A. Nauck, S. Durán‐García et al. · Diabetes Obesity and Metabolism · 2015 · 226 citations

Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial

S. Matthäei, Keith Bowering, Katja Rohwedder et al. · Diabetes Care · 2015 · 147 citations

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Michael A. Nauck, Stefano Del Prato, S. Durán‐García et al. · Diabetes Obesity and Metabolism · 2014 · 114 citations